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Abstract
Background: Recent scientiﬁc reports have shown that older persons trea-
ted with antipsychotics for dementia-related behavioural symptoms have
increased mortality. However, the impact of these drugs prescribed during
hospitalization has rarely been assessed. We aimed to investigate whether
antipsychotics are associated with an increased risk of mortality during hos-
pitalization and at 3-month follow-up in elderly inpatients.
Methods: We analyzed data gathered during two waves (2010 and 2012)
by the REPOSI (Registro Politerapie Società Italiana Medicina Interna). All
new prescriptions of antipsychotic drugs during hospitalization, whether
maintained or discontinued at discharge, were collected, and logistic
regression models were used to analyze their association with in-hospital
and 3-month mortality. Covariates were age, sex, the Short Blessed Test
(SBT) score, and the Cumulative Illness Rating Scale.
Results: Among 2703 patients included in the study, 135 (5%) received
new prescriptions for antipsychotic drugs. The most frequently prescribed
antipsychotic during hospitalization and eventually maintained at dis-
charge was haloperidol (38% and 36% of cases, respectively). Patients
newly prescribed with antipsychotics were older and had a higher Cumu-
lative Illness Rating Scale comorbidity index both at admission and at
discharge compared to those who did not receive a prescription. Of those
prescribed antipsychotics, 71% had an SBT score ≥10 (indicative of
dementia), 12% had an SBT score of 5–9 (indicative of questionable
dementia); and 17% had an SBT score <5 (indicative of normal cognition).
In-hospital mortality was slightly higher in patients prescribed antipsychotic
drugs (14.3% vs 9.4%; P = 0.109), but in multivariate analysis only male
sex, older age, and higher SBT scores were signiﬁcantly related to mortal-
ity during hospitalization. At 3-month follow-up, only male sex, older age,
and higher SBT scores were associated with mortality.
Conclusion: We found that the prescription of antipsychotic drugs during
hospitalization was not associated with in-hospital or follow-up mortality.
Short-term antipsychotic prescriptions (for acutely ill patients) may have a
different effect than long-term, repeated prescriptions.
INTRODUCTION
During the course of dementia, up to 80% of
patients develop behavioural and neuropsychiatric
symptoms (BPSD), including agitation, aggression,
delusions, hallucinations, wandering, depression,
and sleep disturbances.1 The presence of BPSD
leads to worsening functional and cognitive status,
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and these symptoms often require both non-
pharmacological and pharmacological treatment.
Antipsychotics have been chosen as ﬁrst-line
treatment of BPSD for years. However, the 2005/
2008 US Food and Drug Administration (FDA) ‘black
box warning’ about atypical antipsychotics dis-
courages their use for the treatment of BPSD
because of an increased risk of mortality in older per-
sons.2 Before and after the FDA alert, several studies
showed conﬂicting results about mortality due to the
use of both typical and atypical antipsychotics in the
elderly. Some studies did not reveal a higher risk of
mortality,3–6 but several others highlighted an
increased mortality risk in elderly people with
dementia.7–9 Additionally, some found only a short-
term increased mortality.10,11 Musicco et al. found
that the highest mortality risk was related to the pre-
scription of conventional antipsychotics rather than
to atypical ones.12 It is noteworthy that most obser-
vational studies and clinical trials did not enrol hospi-
talized older patients, especially given that
antipsychotics during hospitalization are almost
exclusively prescribed to patients with dementia or
cognitive impairment and related behavioural distur-
bances or delirium.
The aim of this study was to investigate whether
the prescription of antipsychotics after acute hospital
admission was associated with an increased risk of
all-cause mortality during hospitalization and at 3-
month follow-up in elderly inpatients.
METHODS
We analyzed data gathered during 2010 and 2012 by
the REPOSI (Registro Politerapie Società Italiana
Medicina Interna). This database collects information
about hospitalized patients (≥65 years) from 80 inter-
nal medicine and geriatric wards in Italy. Informed
consent was collected by the monitor of the study at
hospital admission. It clearly stated that participation
was voluntary and that subjects could discontinue
participation at any time. An informed consent was
signed by all patients; if the patient was severely cog-
nitively impaired, a proxy (e.g. a close family member)
provided consent. A sample of at least ﬁve patients
consecutively admitted to each participating hospital
ward during a week every 3 months, for a total of
4 weeks a year, was enrolled in the study. A standar-
dized web-based case report form was completed by
the attending physicians; the report included informa-
tion on sociodemographic factors, clinical para-
meters, diagnoses and medications at hospital
admission, hospital stay, and discharge. Adverse
clinical events during hospitalization were also col-
lected. Follow-up was performed 3 months after hos-
pital discharge by telephone interview and collected
data on mortality and re-hospitalization (any acute
hospitalization during follow-up). All recorded data
were collected and checked by a central monitoring
institution (the Mario Negri Institute for Pharmacologi-
cal Research, Milan, Italy). The study was ﬁrst
approved by the Ethics Committee of the IRCCS Cà
Granda Maggiore Policlinico Hospital Foundation
(Milan, Italy) and then by the ethics committee of
each participating centre.
Health status
The Cumulative Illness Rating Scale was employed
to evaluate coexisting diseases.13 The scale was
completed by physicians during the clinical examina-
tion. For each patient, the disease and impairment of
major organ systems were rated on scale of 1 to
5, with 1 indicating no impairment to that organ or
system; 2, mild impairment that does not interfere
with normal activity, may require treatment, and has
a very good prognosis; 3, moderate impairment that
interferes with normal activity, has a good prognosis,
but requires treatment; 4, severe impairment that is
disabling, urgently requires treatment, and has a
guarded prognosis; 5, extremely severe impairment
that is life-threatening, urgently requires treatment
(which may not be available), and has a bad progno-
sis. The scores were integrated and a comorbidity
index was derived.
Cognitive status
The Short Blessed Test (SBT) was used to evaluate
patients’ cognitive status. It was performed within
2 days of hospital admission. SBT is a six-item
orientation–memory–concentration test that has been
validated as a measure of cognitive impairment.14
The following commonly used cut-offs were
employed to classify cognition: (i) 0–4 points, normal;
(ii) 5–9 points, questionable impairment; and
(iii) 10–28 points, impairment consistent with demen-
tia. In this study, we present the mean values of the
SBT scores.
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Prescription of antipsychotic drugs
Patients who had an antipsychotic drug newly pre-
scribed during hospitalization, whether maintained or
discontinued at discharge, were included in the ‘anti-
psychotic treatment’ group, while all the other
patients were included into the ‘no antipsychotic
treatment’ group. The antipsychotic drugs we con-
sidered were promazine, chlorpromazine, olanzapine,
levomepromazine, haloperidol, amisulpride, clotia-
pine, tiapride, zuclopenthixol, quetiapine, risperidone,
periciazine, levosulpiride, and clozapine. Prescrip-
tions of antipsychotics during follow-up were col-
lected. No one in the ‘no antipsychotic treatment’
group was prescribed an antipsychotic within
3 months of discharge. Patients who had been pre-
scribed an antipsychotic drug before hospital admis-
sion were included in the ‘no antipsychotic
treatment’ group (n = 70).
Statistical analysis
Sociodemographic and clinical characteristics of the
sample according to prescription of antipsychotics
were described using univariate analysis (mean or
percentage), and χ2 and ANOVA were used to test dif-
ferences. Logistic regression models were run to
analyze the association of antipsychotic prescription
with in-hospital mortality and status at the 3-month
follow-up. Covariates were age, sex, SBT score, and
Cumulative Illness Rating Scale comorbidity index
score.
Statistical analysis was performed with STATA ver-
sion 12.0 software (College Station, Texas, USA).
RESULTS
A total of 2703 patients were included in the study,
and 135 (5%) were newly prescribed with an antipsy-
chotic drug. The average length of hospital stay for
all patients was 9 days (range 6–14 days).
The most frequent diagnoses at hospital admission
were diabetes mellitus (28.0%), cerebrovascular dis-
ease (21.6%), coronary heart disease (22.0%), chronic
obstructive pulmonary disease (24.8%), malignancy
(16.0%), heart failure (17.8%), gastric diseases
(22.0%), gut diseases (13.9%) and arthritis (10.5%).
The most frequently prescribed antipsychotics dur-
ing hospitalization and at discharge were haloperidol
(38% and 36%, respectively), promazine (28% and
20%) and quetiapine (12% and 11%). Daily doses ran-
ged from 0.5 to 5.0 mg for haloperidol, 10 to 50 mg
for promazine, and 25 to 150 mg for quetiapine. The
mean doses were 1.5, 18, and 47 mg, respectively.
The most frequent disturbances for which antipsycho-
tics were prescribed were acute delirium, agitation,
hallucinations, wandering, and aggressiveness.
The ‘no antipsychotic treatment’ group included a
slightly smaller percentage of women than the ‘anti-
psychotic treatment’ group (49.6% vs 66.7%;
P < 0.001) (Table 1). The mean age for the ‘no anti-
psychotic treatment’ group was 78.9  7.3 years
compared to 82.5  7.6 years for the ‘antipsychotic
treatment’ group (P < 0.001) (Table 1).
With regard to cognitive status, the ‘antipsychotic
treatment’ group had a higher mean STB score than
the ‘no antipsychotic treatment’ group (13.9 vs
8.8 points; P < 0.001) (Table 1). Among the ‘antipsy-
chotic treatment’ group, 71% had an SBT score ≥10
Table 1 Characteristics of the sample by prescription of antipsychotic drugs
No antipsychotic treatment group Antipsychotic treatment group
(n = 2498) (n = 135)
Mean  SD Mean  SD P-value
Age 78.9  7.3 82.5  7.6 <0.001
CIRS comorbidity index score at admission 2.9  1.8 3.3  1.8 0.032
CIRS comorbidity index score at discharge 3.1  1.9 3.6  2.1 0.004
Short Blessed Test 9.1  7.6 15.4  9.3 <0.001
No antipsychotic treatment group Antipsychotic treatment group
n (%) n (%) P-value
Sex (female) 1239 (49.6%) 90 (66.7%) <0.001
In-hospital mortality 144 (5.8%) 8 (5.9%) 0.938
Follow-up mortality 156 (9.1%)† 14 (14.3%)‡ 0.087
†Follow-up available for 1714 persons.
‡Follow-up available for 98 persons.
CIRS, Cumulative Illness Rating Scale.
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(indicative of dementia); 12% had an SBT score of
5–9 (indicative of questionable dementia); and 17% a
SBT score <5 (indicative of normal cognition).
The Cumulative Illness Rating Scale comorbidity
index was higher in the ‘antipsychotic treatment’
group at admission (3.3 vs 2.9, P < 0.03) and at dis-
charge (3.6 vs 3.1, P < 0.005) (Table 1).
All-cause in-hospital mortality was similar between
patients taking antipsychotics and those who did not
(5.8% vs 5.9%; P = 0.938). Mortality was lower at the
3-month follow-up in the ‘no antipsychotic treatment’
group than in the ‘antipsychotic treatment’ group
(9.1% vs 14.3%), but the difference was not statisti-
cally signiﬁcant (Table 1). In addition, the re-
hospitalization rate was similar for both groups.
In multivariate analysis, only older age, male sex,
and a higher SBT score were signiﬁcantly associated
with in-hospital mortality, but they were not signiﬁ-
cantly associated with the prescription of antipsycho-
tics (Table 2).
At follow-up, male sex, older age, and higher SBT
scores were the only factors associated with mortal-
ity in multivariate analysis (Table 3). When the
analyses were performed after exclusion of the few
patients with SBT scores indicative of normal cogni-
tion (regardless of antipsychotic prescription), the
main results did not change (data not shown). Addi-
tionally, the same analyses were run after exclusion
of the 70 patients who had already been prescribed
antipsychotic drugs before hospital admission with-
out any change in the main results (data not shown).
DISCUSSION
The main ﬁnding of this study is that prescribing anti-
psychotics to elderly inpatients, who in most cases
were cognitively impaired, was not associated with
mortality during hospitalization or at 3-month follow-
up after discharge.
Results of previous studies on antipsychotics and
mortality have shown inconsistent results. Findings
are also difﬁcult to compare because studies have
been performed in different settings, used varying
samples, and evaluated different drugs. The meta-
analysis by Schneider et al. showed a small increase
in the risk of death with antipsychotic drugs com-
pared with placebo.8 Langballe et al. showed an
increased mortality risk associated with the use of
antipsychotics in a large population-based sample of
dementia outpatients.7 Similarly, another study
reported an increased risk of death for patients pre-
scribed conventional or atypical antipsychotics.9
Some authors reported a high risk of mortality but
only in the ﬁrst 30 days of prescription for haloperi-
dol.11 A recent retrospective case–control study of a
very large number of older persons with dementia
showed that the absolute effect of antipsychotics on
mortality may be higher than previously reported and
may increases with dosage.15 Suh and Shah evalu-
ated Korean nursing-home patients affected by Alz-
heimer’s disease and prescribed antipsychotics; they
reported that those taking antipsychotics had a lower
mortality rate than those not taking antipsychotics.16
Raivio et al. examined the impact of atypical and
conventional antipsychotics on mortality among eld-
erly institutionalized Finnish patients with dementia
and showed that the use of neither atypical antipsy-
chotics nor conventional ones increased mortality or
hospital admission.5 Haupt et al. found an insigniﬁ-
cant increase in mortality during treatment with ris-
peridone in dementia patients.4
Table 2 OR and 95%CI testing the association of antipsychotic
prescription, demographic, and clinical characteristics with in-
hospital mortality
Multivariate analysis
Independent variables OR (95%CI) P-value
Age (years) 1.02 (0.99–1.05) 0.072
Female sex 0.54 (0.36–0.80) 0.002
Short Blessed Test score 1.08 (1.05–1.10) <0.001
CIRS comorbidity index at
admission score
1.06 (0.96–1.18) 0.261
Antipsychotic drugs (yes vs no) 0.64 (0.26–1.52) 0.306
CI, conﬁdence interval, CIRS, Cumulative Illness Rating Scale; OR, odds
ratio.
Table 3 OR and 95%CI testing the association of antipsychotic
prescription, demographic, and clinical characteristics with mortal-
ity at follow-up
Multivariate analysis
Independent variables OR (95%CI) P-value
Age (years) 1.05 (1.02–1.07) <0.001
Female sex 0.48 (0.33–0.68) <0.001
Short Blessed Test score 1.04 (1.01–1.06) <0.001
CIRS comorbidity index at
admission score
1.1 (0.99–1.19) 0.06
Antipsychotic drugs (yes vs no) 1.1 (0.58–2.20) 0.716
CI, conﬁdence interval, CIRS, Cumulative Illness Rating Scale; OR, odds
ratio.
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There have been few reports on antipsychotics
prescription in elderly inpatients. In part, this is
because hospitalized individuals have speciﬁc char-
acteristics that make difﬁcult to perform such studies.
Such characteristics include different acute diseases,
multiple new drug prescriptions, the short duration of
surveillance, and possible concurrent adverse clinical
events. Discrepancies between studies of hospital
populations may be due to any of these reasons.
Interestingly, we found that in-hospital mortality
was higher in elderly patients with a higher STB
score, regardless of the administration of antipsycho-
tics during hospitalization. This result conﬁrms previ-
ous ﬁndings from the REPOSI, as well as other
studies, that reported that patients with dementia,
compared with those without such diagnosis, have
worse hospitalization outcomes.17 Lopez et al.
showed that the presence of psychiatric symptoms
was linked to higher mortality risk after adjustment
for antipsychotics exposure.3 Guijarro et al. showed
that patients with dementia have a longer in-hospital
stay and higher in-hospital mortality than those with-
out dementia.18
Limitations and strengths
Few patients (5%) in this study were newly treated
with antipsychotic drugs during hospitalization. This
may be because of the inﬂuence of warnings from
the FDA and the Italian Medicines Agency on clinical
practice. Both the FDA and the Italian Medicines
Agency do not approve the use of antipsychotics for
the treatment of BPSD in the elderly because of the
uncertainty in the increased mortality risk, especially
for cardiovascular events. Therefore, clinicians prefer
using other strategies, such as benzodiazepines,
antidepressants, or non-pharmacological measures.
A previous report on antidepressant prescriptions in
the REPOSI did show that being affected by demen-
tia was associated with antidepressant prescription,
even if a speciﬁc diagnosis of depression was not
reported,19 indicating that antidepressants were
probably prescribed for behavioural disturbances.
Another limitation of our study was that there were
too few prescriptions to analyze differences between
typical and atypical antipsychotics and mortality.
Also, we did not have data on adherence to prescrip-
tion instructions during the follow-up. Follow-up data
were available for the 68.5% of the ‘no antipsychotic
group’ and for 72.5% of the ‘antipsychotic group’.
Additionally, it should be noted that patients are
sometimes admitted to hospital on the selective
basis of ward characteristics, severity of disease,
associated medical conditions, and admissions poli-
cies that may vary from hospital to hospital. Moreo-
ver, doctors’ attitudes towards prescribing
antipsychotics may differ.
One of the strengths of the study was the evalua-
tion of antipsychotic prescriptions during acute hos-
pitalization. It is important to evaluate the impact of
antipsychotic prescriptions on inpatients because
their short-term use in acutely ill patients may have a
different effect than long-term prescriptions at home.
Treating older individuals with BPSD during acute
hospitalization is often difﬁcult and challenging. Fur-
ther studies on short-term antipsychotic prescriptions
and their adverse events may have practical clinical
value. Beyond mortality, interactions with other drugs
and the cumulative anticholinergic load should be
taken into account when prescribing this therapy.
Another strength is the multicentre design of the
REPOSI, which collects data from internal medicine
and geriatric wards throughout Italy, resulting in a
sample representative of the elderly hospitalized pop-
ulation of the country. Moreover, the inclusion of
patients admitted during the same 4-week period
helps to balance the common effect of seasons on
acute diseases leading to hospitalization.
In conclusion, our study showed that the use of
antipsychotics is not associated with increased mor-
tality risk during hospitalization or at 3 months after
discharge. The creation of comprehensive guidelines
for the use of antipsychotics during hospitalization in
older persons is needed.
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